Oruka Therapeutics, Inc. Number of Reportable Segments
Oruka Therapeutics, Inc. (ORKA) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-10
- Oruka Therapeutics, Inc. number of reportable segments for the quarter ending 2025-03-31 was 100.00%.
- Oruka Therapeutics, Inc. number of reportable segments for fiscal 2025 was 100.00%.
pure
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 11 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 100.00% 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | 100.00% 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | 100.00% 10-Q · filed 2025-08-11 | ||||
| 2025-03-31 | 100.00% 10-Q · filed 2025-05-14 | ||||
| 2024-12-31 | 100.00% 10-K · filed 2025-03-06 |
Segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month |
|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-10 | |
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |